This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Sign In   |   Register
ESC/EAS on PCSK9

European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

A joint consensus statement from the European Society of Cardiology and the European Atherosclerosis Society Task Force.

Publication in full

Authors

Ulf Landmesser, M. John Chapman, Michel Farnier, Baris Gencer, Stephan Gielen, G. Kees Hovingh, Thomas F. Lüscher, David Sinning, Lale Tokgözoglu, Olov Wiklund, Jose Luis Zamorano, Fausto J. Pinto, and Alberico L. Catapano on behalf of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Editorial

To be announced

Membership Software Powered by YourMembership  ::  Legal